Synopsys Ownership
| SNPS Stock | USD 389.83 4.10 1.04% |
Shares in Circulation | First Issued 1989-12-31 | Previous Quarter 156.1 M | Current Value 161.7 M | Avarage Shares Outstanding 132 M | Quarterly Volatility 36.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Synopsys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Synopsys Stock Ownership Analysis
About 92.0% of the company shares are owned by institutional investors. The book value of Synopsys was at this time reported as 148.9. The company recorded earning per share (EPS) of 7.33. Synopsys had not issued any dividends in recent years. The entity had 2:1 split on the 24th of September 2003. Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. The company was incorporated in 1986 and is headquartered in Mountain View, California. Synopsys operates under SoftwareInfrastructure classification in the United States and is traded on NASDAQ Exchange. It employs 16361 people. To find out more about Synopsys contact Sassine Ghazi at 650-584-5000 or learn more at https://www.synopsys.com.Besides selling stocks to institutional investors, Synopsys also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Synopsys' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Synopsys' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Synopsys Quarterly Liabilities And Stockholders Equity |
|
Synopsys Insider Trades History
Less than 1% of Synopsys are currently held by insiders. Unlike Synopsys' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Synopsys' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Synopsys' insider trades
Synopsys Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Synopsys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Synopsys backward and forwards among themselves. Synopsys' institutional investor refers to the entity that pools money to purchase Synopsys' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pictet Asset Manangement Sa | 2025-06-30 | 2.5 M | Ubs Asset Mgmt Americas Inc | 2025-06-30 | 1.9 M | Van Eck Associates Corporation | 2025-06-30 | 1.9 M | Alliancebernstein L.p. | 2025-06-30 | 1.9 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.9 M | Clearbridge Advisors, Llc | 2025-06-30 | 1.6 M | Northern Trust Corp | 2025-06-30 | 1.6 M | Amvescap Plc. | 2025-06-30 | 1.6 M | Aristotle Capital Management Llc | 2025-06-30 | 1.6 M | Vanguard Group Inc | 2025-06-30 | 15.1 M | Blackrock Inc | 2025-06-30 | 12.8 M |
Synopsys Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Synopsys insiders, such as employees or executives, is commonly permitted as long as it does not rely on Synopsys' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Synopsys insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gopal Ajei over two weeks ago Insider Trading | ||
Gopal Ajei over a month ago Insider Trading | ||
Gopal Ajei over a month ago Insider Trading | ||
Gopal Ajei over two months ago Insider Trading | ||
Gopal Ajei over two months ago Insider Trading | ||
Gopal Ajei over three months ago Insider Trading | ||
Richard Mahoney over six months ago Disposition of 6343 shares by Richard Mahoney of Synopsys at 506.071 subject to Rule 16b-3 | ||
Richard Mahoney over six months ago Disposition of 10322 shares by Richard Mahoney of Synopsys at 505.9868 subject to Rule 16b-3 | ||
De Geus Aart over a year ago Disposition of 186551 shares by De Geus Aart of Synopsys subject to Rule 16b-3 | ||
De Geus Aart over a year ago Disposition of 5448 shares by De Geus Aart of Synopsys at 89.76 subject to Rule 16b-3 | ||
De Geus Aart over a year ago Disposition of 4340 shares by De Geus Aart of Synopsys at 89.76 subject to Rule 16b-3 | ||
Richard Mahoney over a year ago Disposition of 3411 shares by Richard Mahoney of Synopsys at 590.21 subject to Rule 16b-3 |
Synopsys' latest congressional trading
Congressional trading in companies like Synopsys, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Synopsys by those in governmental positions are based on the same information available to the general public.
| 2025-10-22 | Representative Lisa McClain | Acquired Under $15K | Verify | ||
| 2025-10-13 | Representative Michael McCaul | Acquired Under $15K | Verify | ||
| 2025-09-12 | Representative Valerie Hoyle | Acquired Under $15K | Verify | ||
| 2025-08-15 | Representative Julie Johnson | Acquired Under $15K | Verify | ||
| 2024-11-07 | Representative Byron Donalds | Acquired Under $15K | Verify | ||
| 2024-05-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify |
Synopsys Outstanding Bonds
Synopsys issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Synopsys uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Synopsys bonds can be classified according to their maturity, which is the date when Synopsys has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| SNV 5625 15 FEB 28 Corp BondUS87164DVJ61 | View | |
| SYNCHRONY FINL 395 Corp BondUS87165BAM54 | View | |
| SYNCHRONY FINL 37 Corp BondUS87165BAL71 | View | |
| SYF 2875 28 OCT 31 Corp BondUS87165BAR42 | View | |
| SYF 725 02 FEB 33 Corp BondUS87165BAU70 | View | |
| SNX 265 09 AUG 31 Corp BondUS87162WAK62 | View | |
| SNX 175 09 AUG 26 Corp BondUS87162WAF77 | View | |
| Synovus 59 percent Corp BondUS87161CAM73 | View |
Synopsys Corporate Filings
| 13th of November 2025 Other Reports | ViewVerify | |
8K | 12th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 23rd of September 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of September 2025 An amendment to a previously filed Form 8-K | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Synopsys Stock Analysis
When running Synopsys' price analysis, check to measure Synopsys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synopsys is operating at the current time. Most of Synopsys' value examination focuses on studying past and present price action to predict the probability of Synopsys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synopsys' price. Additionally, you may evaluate how the addition of Synopsys to your portfolios can decrease your overall portfolio volatility.